Korro Bio (NASDAQ:KRRO - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect Korro Bio to post earnings of ($2.60) per share and revenue of $0.13 million for the quarter.
Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.60) by $0.11. The company had revenue of $2.55 million for the quarter, compared to analyst estimates of $0.13 million. On average, analysts expect Korro Bio to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.
Korro Bio Stock Up 2.1 %
Shares of KRRO stock traded up $0.32 during trading hours on Friday, reaching $15.72. 8,288 shares of the stock traded hands, compared to its average volume of 91,035. The business has a fifty day moving average price of $17.91 and a 200 day moving average price of $34.92. Korro Bio has a 1-year low of $11.13 and a 1-year high of $98.00. The firm has a market capitalization of $147.63 million, a PE ratio of -1.67 and a beta of 2.66.
Analyst Upgrades and Downgrades
KRRO has been the topic of several research analyst reports. Oppenheimer initiated coverage on shares of Korro Bio in a report on Friday, January 10th. They set an "outperform" rating and a $155.00 price target on the stock. HC Wainwright cut their price target on Korro Bio from $115.00 to $100.00 and set a "buy" rating for the company in a research note on Thursday. Chardan Capital began coverage on Korro Bio in a research note on Wednesday, April 16th. They issued a "buy" rating and a $25.00 price target for the company. Cantor Fitzgerald upgraded Korro Bio to a "strong-buy" rating in a report on Tuesday, April 29th. Finally, Royal Bank of Canada reduced their target price on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a research note on Wednesday, March 19th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $112.75.
Read Our Latest Report on KRRO
About Korro Bio
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Featured Articles
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
